secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002689
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma appoints Robert J. DelAversano as principal financial and accounting officer, effective Jan 5, 2024
--------------------------------------------------------------------------------

- Robert J. DelAversano, 52, CPA and former VP Finance, becomes principal financial and accounting officer.
- Brian Ford removed as interim-CFO; remains as financial consultant on an as-needed basis.
- DelAversano receives $290,000 base salary, up to 30% target bonus, and 42,000 stock options at $2.125 per share.
- DelAversano joined Acasti in Nov 2023; prior experience at OncoSec and Brio Financial Group.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/acst-20240105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer